19:45 , Nov 6, 2018 |  BC Innovations  |  Distillery Techniques

Assays and screens; biomarkers

TECHNOLOGY: Cellular assays; gene profiling; tissue markers Gene profiling coupled with cell-based assays of patient samples could help predict drug responses in AML patients. In tumor samples from 363 patients, whole-exome sequencing plus genotyping of...
17:57 , Oct 25, 2018 |  BC Innovations  |  Distillery Therapeutics

Infectious disease

INDICATION: Coronavirus; influenza virus; HIV/AIDS; Ebola Cell culture and rat studies identified lipopeptide-based inhibitors of MERS-CoV S protein, Ebola virus glycoprotein and HIV env that could help treat Middle East respiratory syndrome coronavirus (MERS-CoV), Ebola...
17:43 , Oct 24, 2018 |  BC Week In Review  |  Company News

Anaeropharma and Chugai partner to discover cancer drugs using anaerobic bacteria

Anaeropharma Science Inc. (Tokyo, Japan) and Chugai Pharmaceutical Co. Ltd. (Tokyo:4519) partnered to conduct joint research to discover cancer treatments using Anaeropharma's...
23:06 , Oct 11, 2018 |  BC Week In Review  |  Clinical News

FDA approves Roche's Hemlibra for hemophilia without inhibitors

FDA approved an sBLA for Hemlibra emicizumab-kxwh from Roche (SIX:ROG; OTCQX:RHHBY) to reduce the frequency of bleeding episodes in adults and children with hemophilia A without Factor VIII inhibitors. The company said it is now...
22:59 , Oct 11, 2018 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Melanoma Cell culture and mouse studies suggest the generic antibiotic nifuroxazide could help treat melanoma. In two human metastatic melanoma cell lines, nifuroxazide plus the BRAF inhibitor Zelboraf vemurafenib and the MEK inhibitor Mekinist...
22:58 , Oct 11, 2018 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Basal cell carcinoma (BCC) Mouse studies suggest combining LGR5, LRP6 or PORCN inhibitors with Erivedge vismodegib could help treat BCC. In two mouse models of BCC, diphtheria toxin-mediated depletion of LGR5 decreased tumor burden...
21:44 , Oct 10, 2018 |  BC Extra  |  Politics & Policy

China adds insurance coverage for 17 cancer therapies

China's National Medical Insurance Administration added 17 cancer drugs to the National Reimbursement Drug List (NRDL) for coverage by the country's medical insurance program. The prices will go into effect by the end of October...
01:14 , Oct 6, 2018 |  BioCentury  |  Finance

Large cap comeback

The biotech sector continued to be a stock pickers’ market through 3Q18 as there was a near even split between global biotech stocks that gained and lost value in the quarter. While 1H18 saw investors...
20:07 , Oct 5, 2018 |  BC Week In Review  |  Company News

Chugai grants Lilly rights to preclinical diabetes candidate

Chugai Pharmaceutical Co. Ltd. (Tokyo:4519) granted Eli Lilly and Co. (NYSE:LLY) worldwide rights to develop and commercialize preclinical Type II diabetes candidate OWL833. Chugai will receive $50 million up front and is eligible for undisclosed...
19:37 , Sep 10, 2018 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Non-small cell lung cancer (NSCLC) Mouse studies suggest combined inhibition of EGFR and β-catenin could help treat EGFR-mutant NSCLC. In two xenograft mouse models of EGFR-mutant NSCLC, the EGFR inhibitor Tarceva erlotinib and a...